A study presented at the EANM'26 congress shows that a CAIX-targeted PET imaging agent outperforms standard methods in detecting common kidney cancer lesions.
Key facts
- •The CAIX-targeted agent [⁶⁸Ga]Ga-DPI-4452 detected 97.9% of ccRCC lesions compared to 47.1% for ¹⁸F-FDG.
- •Tumor uptake with the new agent was approximately five times higher than with ¹⁸F-FDG, with a tumor-to-background ratio 10 times greater.
- •The new imaging approach detected all identified brain and lung metastases in the study cohort.
- •Clinical management or disease staging was altered for 30.9% of patients following the use of the new imaging agent.
- •Researchers identified a need for longer-term studies to determine if these imaging improvements lead to better patient outcomes.
A new PET imaging approach using the agent [⁶⁸Ga]Ga-DPI-4452 detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), significantly outperforming the standard radiotracer ¹⁸F-FDG. Findings from a prospective multicenter study of 68 patients were presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26).
By the numbers
Superior Detection Capabilities
The study evaluated 492 true lesions across 68 patients with renal cell carcinoma. While standard ¹⁸F-FDG PET/CT detected 56.7% of these lesions, the CAIX-targeted [⁶⁸Ga]Ga-DPI-4452 PET/CT identified 90.9%. The advantage was most pronounced in ccRCC, where the new agent achieved a 97.9% detection rate compared to 47.1% for the standard method. Patient-level diagnostic accuracy for ccRCC reached 98.2% with the new approach, versus 77.2% for ¹⁸F-FDG. Lead author Esra Arslan noted that CAIX serves as a highly selective biological target, as it is expressed at high rates in ccRCC but remains minimal in healthy renal tissue. This allows for clearer differentiation between tumors and surrounding tissue. In contrast, ¹⁸F-FDG measures glucose metabolism, which can be complicated by high physiological uptake in the kidneys and low uptake in some low-grade tumors.
Clinical Impact and Future Applications
The use of [⁶⁸Ga]Ga-DPI-4452 PET/CT led to changes in clinical management or disease staging for 30.9% of patients, compared to 5.9% with the standard method. These changes included the identification of previously undetected recurrent disease and the detection of metastases that resulted in upstaging. Additionally, the new agent helped avoid unnecessary interventions by excluding findings that appeared positive on ¹⁸F-FDG scans. Researchers suggest the agent could eventually assist in initial staging, restaging during suspected recurrence, or as part of a theranostic approach to identify candidates for [¹⁷⁷Lu]Lu-DPI-4452 treatment. However, Arslan emphasized that further validation in larger, multicenter studies is required before the agent can be considered a new molecular imaging standard.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Medical Xpress.
